Skip to main content

Target selection for CAR-T therapy


Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the treatment of several hematological malignancies. However, the translation of the existing achievements into the treatment of other tumors, especially solid tumors, is not smooth. In addition to the optimization of CAR structures, preparation, and clinical protocols, rational selecting and utilizing the targets was more pivotal. In this review, the criteria for target selection and some new strategies for targets utilization were summarized and discussed. This systematic review will help researchers better understand how the efficacy and safety of CAR-T treatment would be affected by targets and thus more rationally select targets and conduct clinical trials.


With the elucidation of mechanisms of tumor development, different approaches have been exploited to fight against cancers, such as chemotherapy, radiation therapy, and kinase inhibitors. Despite great advances achieved, complete remission, especially durable remission, for unresectable malignancies remains rare. To improve cancer treatments, high level of enthusiasm is always devoted to the research on novel cancer therapies, including immunotherapy.

Owing to the robust and long-lasting antitumor functions, chimeric antigen receptor modified-T (CAR-T) cells achieved significant success [1, 2]. The recognition and clearance of tumor cells by CAR-T cells are dependent on chimeric antigen receptor (CAR) molecule but not the binding of traditional T cell receptor (TCR) and human leukocyte antigen (HLA), so that the immune escape caused by low expression of HLA in tumor cells could be overcomed. CAR-T cells can differentiate into memory T cells, by which a long-term antitumor activity can be established. Due to these advantages, CAR-T cells exhibit potent antitumor activity in the treatment of hematological tumors.

The complete remission rate (CRR) of CD19-targeted CAR-T (CAR-T-19) cells in the treatment of B cell acute lymphocytic leukemia (B-ALL) could be more than 90% [2, 3]. Outstanding antitumor efficiency in other hematologic malignancies such as multiple myeloma (MM) [4,5,6,7] and B cell lymphoma have also been achieved [8,9,10,11]. In 2017, the US Food and Drug Administration approved the drug CTL019 (tisagenlecleucel-T, Novartis) for the treatment of B-ALL, which was viewed as a milestone of immunotherapy.

As an emerging tumor treatment strategy, CAR-T therapy still needs further exploration to expand its clinical application, and further optimization is also needed to solve real-life clinical problems. After 20 years of exploration, we have basically understood the main factors that determine the function of CAR molecule, such as co-stimulatory molecules [9] and extra-membrane spacer regions [12]. These research results have transformed into a variety of CAR structures. Generally speaking, the second generation CAR structure containing one single co-stimulatory molecule has shown sufficient antitumor function and safety, and is the main structure used in clinic at present [13]. At the same time, advances in the preparation of CAR-T products [14,15,16], the protocols for clinical implementation [17,18,19], and the management of side effects [20, 21] have greatly improved the clinical efficacy and application scenarios.

Given that the CAR-T therapy has possessed with mature CAR structure, preparation, and clinical protocols, how to choose and utilize the target becomes the key to determine its potential.

There are no uniform guiding criteria for target selection, and the criteria are often needed to be modified according to the actual clinical needs. For example, the most urgent need for solid tumors treatment is to improve efficiency at present; therefore, choosing a target with high specificity and high coverage is of greatest value. However, this has not been a significant hurdle for the treatment of ALL and B lymphoma right now, because the CD19 or CD20 has been validated to be of sufficient coverage and specificity. Instead, the most urgent need is to further improve CRR and prevent recurrence [22, 23].

Target selection is a very important determinant, which requires researchers to implement a comprehensive assessment. But at present, there are few reviews which detailed and discussed this issue. Therefore, in this paper, we will review and discuss the principles for target selection and the new strategies for target utilization. We believe this will help the scientists to better design and implement CAR-T therapies.

Coverage and specificity

CAR molecule targets tumor cells’ surface antigens. Not only proteins but also carbohydrate and glycolipid molecules could be the potential targets. The interaction between CAR and targets leads to the formation of immune synapses, with which the contact-dependent cytotoxicity occurs. To achieve prominent tumor clearance, CAR-T cells should target the vast majority of tumor cells, that is, the selected target antigen should have sufficient coverage on the tumor cells. At present, most of the CART therapies with good clinical effect meet the selection criteria of high coverage, such as CD19, CD20, and B cell maturation antigen (BCMA) [24]. In addition, there are some other targets with high coverage that deserve further verification, such as C-type lectin-like molecule-1 (CLL-1) for acute myeloid leukemia blasts [25].The specificity of selected targets should be good enough to prevent CAR-T cells from causing serious organ damage. There are two main toxic side effects in the CAR-T treatment, one is cytokine release syndrome (CRS) caused by activated immune cells and the other one is “off-tumor” effect caused by damage on non-tumor cells. Compared with CRS, which could be effectively managed, the “off-tumor” effect which can cause serious organ damage or even death [26] is difficult to distinguish from the antitumor effect.

Therefore, an ideal target should be of high coverage and high specificity to guarantee both effectiveness and safety. However, the “ideal” target is almost non-existent in reality.

Take CD19 as an example, the most widely used target in CAR-T therapy, which has been validated to be effective and safe to treat B-ALL, chronic lymphocytic leukemia (CLL), and B cell lymphoma. CD19 is widely and confinedly expressed throughout the entire phase of B cell development until terminal differentiation into plasma cells (Fig. 1a). Therefore, CD19 has perfect coverage for B cell malignancies, which made CAR-T-19 treatment achieved very high CRR.

Fig. 1
figure 1

Schematic description of the expression of CD19 and CD22. a The expression patterns of CD19 and CD22 during B cell development. b Gene mutation is the main mechanism of antigen-negative relapse after CAR-T-19 treatment. This picture is quoted from an article published in Nature Medicine by Orlando et al. in 2018 [27]. c Silence of expression, rather than gene mutation, is the main cause of CD22 loss after CAR-T treatment. This picture is quoted from an article published in Nature Medicine by Fry et al. in 2018 [28]

However, in terms of specificity, CD19 is not an ideal target. Along with the antitumor effect of CAR-T-19, normal B cells will also be cleared, which leads to long-term B cell aplasia. Fortunately, B cell aplasia could be tolerated by patients due to effective clinical management. The same is true for CD20 and BCMA. Although they are not strictly expressed on tumor cells, these CAR-T treatments have shown outstanding clinical prospects due to high coverage and tolerable off-target effects.

Therefore, we insist that the coverage for single-target CAR-T treatment should be high enough. For its specificity, the off-tumor effect needs to be evaluated and tested strictly. In the implementation, the treatment intensity which needs to be accordingly set within a proper window is determined by toxic side effects. When the off-tumor side effects can be tolerated, specificity could be compromised in practice (Table 1). The experience on coverage and specificity may not be suitable for solid tumors due to the inherent heterogeneity. For solid tumors, we can hardly get a target of which the coverage is good enough. Moreover, most of the targets tested currently would bring significant off-target effects, so the treatment intensity is often limited, which in turn further weakens the effectiveness. Therefore, the treatment of solid tumors might require combination of multiple targets and endogenous antitumor effects, which will be discussed later.

Table 1 Determinant of target selection for CAR-T therapy


Coverage and specificity are the basic factors in target screening for CAR-T therapy. In addition, the expression stability of antigens is also fundamental.

With high evolutionary potential brought about by genomic instability, cancer cells could rapidly acquire the phenotypes that prevent immune killing. In CAR-T treatment, losing targets is a very common mechanism for the failure of treatment. Both theory and experience have proved that the less stable the target is, the easier it is for cancer cells to escape from the killing of CAR-T cells. Therefore, as an ideal target, its expression should be fixed. If the expression is floating, the treatment is hard to be effective.

Take CD19 and CD22 as an example, their expression patterns are almost the same (Fig. 1a). From the perspective of coverage and specificity, it is inferred that CAR-T-19 and CAR-T-22 therapy should present similar antitumor potential in the treatment of B cell lymphoma. However, in clinical practice, CAR-T-19 therapy exhibited more significant and persistent antitumor activity [22, 28, 29].

In patients who relapsed after treatment with CAR-T-19 or CAR-T-22, target loss is the most common cause, except for the poor proliferation and persistence of CAR-T cells. One study demonstrated that CD19 gene mutation is the main cause of target loss during CAR-T-19 treatment [27]. Among them, CD19 was not completely silenced but existed in different truncated forms (Fig. 1b). On the contrary, the CD22 was more prone to be silenced by upstream regulations [28], such as signaling pathways or epigenetic modification, rather than gene mutation (Fig. 1c). In general, signaling or epigenetic regulation occurs faster and more often than genomic mutations. In other words, the expression of CD19 is more fixed than that of CD22. We believe that this was the main reason why the clinical response of CAR-T-22 is inferior to that of CAR-T-19. Recently, a report on the substitution of scFV with FMS-like tyrosine kinase-3 ligand [30] provided a novel strategy for overcoming the problem of targeted motif loss caused by gene mutation. In addition to the regulation mechanisms, another reason for the fixed expression of CD19 is that it plays an important role in the survival and proliferation of B cell malignancies. As we know, CD19 is essential to the function of BCR complex, which is necessary for B cell differentiation and survival [31]. B cell malignancies that completely lose CD19 cannot obtain sustained dominant growth, and this also explains why the relapsed B cell malignancies after CAR-T-19 treatment were prone to express truncated CD19 that lost the scFv targeting segment rather than silencing the expression.

In conclusion, the expression of a good target for CAR-T therapy should be fixed, which is determined by its own regulation mechanisms and the importance in maintaining the proliferation of malignant cells (Table 1).

Strategies for improving coverage and specificity

Due to the lack of ideal target, the potential of CAR-T therapy has not been fully realized in many cases [32]. Researchers have designed many novel strategies to improve the coverage and specificity of CAR-T targets.

The most common strategy is to combine different targets.

The first kind of relationship between different targets is 1 or 2 (Fig. 2a). In this approach, two intact CARs could be constructed into one vector [33]. The transfected T cells will express two CARs specific for two different antigens. Full activation could be achieved when each antigen is engaged. When the two antigens are encountered at the same time, the immune response can be further enhanced. This strategy can be generally considered as co-administration of two different normal CAR-T cells. Except for expressing two different CAR molecules, tandem expression of two scFv domains in one CAR molecule can also come up to a similar effect [34,35,36,37]. According to several reports, the relative positional changes between the two scFv domains have an important effect on the function of the CAR molecule [35, 36]. Therefore, the design of such tandem CAR may require more detailed optimization.

Fig. 2
figure 2

Strategies of combining two targets to improve coverage and specificity. a CAR-T cells can be fully activated by antigen-1 or antigen-2 to improve tumor coverage. b CAR-T cells can only be fully activated when antigen-1 and antigen-2 are engaged simultaneously. c CAR-T cells will be inhibited when antigen-2 is present

Extended antigen coverage could guarantee more thorough tumor cell recognition and clearance. For different tumors, the purposes of this multi-target combination strategy are different. For example, a very high CRR for ALL treatment by CAR-T-19 has been achieved, and simultaneous targeting of CD19/CD22 or CD19/CD123 may not significantly improve the initial clinical benefits. However, its main purpose is to prevent CD19-negative recurrence after CAR-T treatment. For most solid tumors, the heterogeneity is very high. Both theory and practice have proved that the efficiency of single-targeted CAR-T therapy was very limited. Therefore, the main purpose of adding a target, such as CAR-T-HER2/IL13Ra2, is to improve the coverage so that more tumor cells can be cleared, which would lead to improved response to CAR-T treatment.

It should be noted that although the 1 or 2 strategy could increase the coverage, it may also increase on-target/off-tumor risks. Therefore, more careful evaluation is required before clinical implementation.

The second kind of relationship between different targets is 1 and 2 (Fig. 2b). In this strategy, the intracellular activating regions of a complete CAR molecule, the CD3ζ and co-stimulatory activation domains, are expressed separately within two half-baked CARs. The CAR-1 provides a CD3ζ-mediated activation signal upon recognition of antigen 1 (just like the 1st generation CAR), and the co-stimulatory signal is provided by the CAR-2 when antigen 2 is engaged. In 2013, Kloss et al. at MSKCC demonstrated that recognition of two targets was necessary for full activation in this design [38]. In that article, the half-baked CAR molecule which provided co-stimulatory signals was called chimeric co-stimulatory receptor.

In this manner, the combinatorial CAR-T cells can become fully activated only when they met with 1positive/2positive target cells. And this combinatorial activation system is considered to hold promising selectivity for solid tumors.

However, it is worrying that the activated T cells might recirculate and encounter 1positive/2negative or 1negative/2positive target cells. Without requiring for full activation, the CAR-Ts might clear these target cells, thus resulting in an “on-target off-tumor” effect.

The third kind of relationship between the two targets is 1 not 2 (Fig. 2c). In this concept, the CAR-Ts’ activation or function would be inhibited by an inhibitory CAR (iCAR) upon expected antigen engagement. In 2013, Fedorov et al. at MSKCC developed such a kind of iCAR molecule [39]. The iCARs were designed to be consisting of scFv domain, hinge, and transmembrane domain just as the common CAR molecule. But the intracellular domain was replaced with the signaling domains of cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or programmed cell death-1 (PD-1). The synthetic receptors were hypothesized to own inhibitory function which was proved to be so subsequently. From a certain point of view, iCAR can also be seen as mimetic PD-1 or CTLA-4.

After a series of verification, the iCARs were proved to be able to selectively limit T cell activation induced by endogenous TCR and exogenous CAR molecule. The antigens expressed in normal tissues but not tumor cells could be used as the iCAR’s targets. But the inhibitory effect was temporary and reversible, thus enabling CAR-T cells to function with the common activating CAR molecule. In this manner, the damage to normal tissues could be diverted without eliminating or irrevocably inhibiting the CAR-T cells.

Extending the targets

The neoantigen derived from gene mutation is an ideal target because it can fully distinguish cancer cells from normal ones. Most of the identified neoantigens are intracellularly expressed and can only be immunogenic in the form of peptide/HLA complex. Therefore, it is generally not considered to be an applicable target for CAR-T treatment.

The concept of using scFv targeting epitope/HLA complex to construct CAR makes it possible for intracellular proteins to be the candidate targets. One example is Wilms’ tumor-1(WT-1) [40], which is an oncogenic transcription factor overexpressed in many malignancies. The researchers obtained WT-1/HLA-A*02:01 complex-specific scFv by phage display technology [41], which was then constructed into traditional CAR molecule. The HLA complex targeted CAR-T cells were then confirmed to be effective to kill tumor cells specifically. The greatest advantage of this strategy is its high specificity, so the potential off-tumor effect can be limited to a very low level. However, it could be anticipated that the stability and coverage of this kind of target might not be good enough. Therefore, in the future clinical application, we believe that the combination use of the peptide/HLA targets is needed. In addition, a fundamental question needs to be carefully studied before this strategy is widely implemented, that is, whether its specificity is really as good as it is supposed to be.

Solid tumors establish a sophisticated composition to support tumor growth, including immunosuppressive microenvironment, unique vascular system, and nutritional environment suitable for tumor growth and so on. The cells involved in the establishment and maintenance of the microenvironment can also be the targets for CAR-T therapy (Fig. 3). For example, the cancer-associated fibroblasts (CAF), which support tumor growth by secreting growth factors, chemokines, and extracellular matrix, could be destroyed by CAR-T cells targeting fibroblast activation protein (FAP) [42], and potent antitumor effects by CAR-T-FAP have been also confirmed [43, 44]. In addition, destroying tumor vascular system [45, 46] and killing cancer stem cells [47, 48] by CAR-T cells have also been proved to be feasible and effective. The strategy that transforms the targets from cancer cells to other cells supporting the growth of tumors also provides a basis for combined application of other treatments.

Fig. 3
figure 3

Other cells that play an important supporting role in the growth of tumors can also be targeted for CAR-T therapy

The CAR-T cells we made generally possess unitary specificity, which means only one target could be recognized. This limits the applicability of CAR-T cells, especially for the treatment of highly heterogeneous solid tumors. It will be meaningful to reform CARs to be specific to wider range of antigens. As early as 2012, the researchers at the University of Pennsylvania (UP) synthesized a novel CAR structure [49], of which the specificity was variable. In this article, the researchers replaced the scFv domain with a modified avidin motif linked to the rest part of CAR molecule. The T cells could recognize different targets with the help of different biotinylated molecules, such as biotinylated tumor-specific antibodies and ligands. The versatility afforded by the novel CAR structure made it feasible for sequential or multiple-target CAR-T therapies achieved within one treatment. Subsequently, there are several similar work published, in which anti-PNE (peptide neo-epitope) scFV [50], leucine zipper [51], anti-5B9-tag scFV [52], and anti-FITC scFV [53] were used to construct the universal CAR.

In this manner, a specific molecule, normally antibodies, works as an adaptor between T cells and tumor cells. Except for controllable specificity, the activity of CARTs activity could also be precisely controlled with titration or removal of the adaptors.

Triggering endogenous immunity

In the treatment of solid tumors, what roles CAR-T cells should play in addition lysis tumor cells is worth further exploration.

There are currently many strategies to improve the accuracy of CAR-T therapy in the treatment of solid tumors, but solid tumors are so complicated (especially with very high heterogeneity) that the CAR-T cells which target a specific target can hardly cover all solid tumor cells, even if multiple targets could be combined. From a certain point of view, CAR-T cells seem to be naturally inadequate for overcoming the heterogeneity obstacle.

Due to the extremely high abundance of TCR in vivo, compared to the CAR-T cells recognizing a specific target, the endogenous tumor-specific T cells (recognizing neoantigen and HLA complexes by TCR) are more likely to fully cover solid tumor cells and thus may eliminate the malignancies more clearly [54, 55]. At present, this view has been accepted by many scientists, and some meaningful exploration has been made [56].

In this scenario, CAR-T cells could be used as therapeutic tools to activate the antitumor activity of endogenous immune system. Many clinical cases have confirmed that lymphocyte infiltration in solid tumors would increase after CAR-T treatment. In addition to CAR-T cells themselves, the infiltration of endogenous dendritic cells (DCs), macrophages, and endogenous T cells could also be increased. In the activation loop (Fig. 4), the neoantigens released after CAR-T cells attacking could activate the more specific endogenous tumor-specific immune response if they are uptaken and presented by antigen-presenting cells. In addition, the CAR-T cells could be modified to release pro-inflammatory factors and form a favorable microenvironment for inflammatory response in the local area of tumors, which would further boost the endogenous tumor immune response. Under this conception, the choice of target in solid tumors CAR-T treatment does not necessarily follow the principles discussed previously. For example, the coverage does not need to be very high, as long as it can ensure that a significant immune response can be triggered.

Fig. 4
figure 4

CAR-T cells can be modified to initiate and boost the endogenous tumor-specific immune response

Switching the original signals

In addition to the heterogeneity mentioned above, the immunosuppressive microenvironment is also an important factor limiting the effectiveness of immunotherapy for solid tumors. Among the factors that establish immunosuppression, the PD-1/PD-L1 axis plays a major role. As we know, the PD-1 receptor could strongly inhibit T cell activation and proliferation upon the interaction with its ligands PD-L1 or PD-L2. The expression of PD-L1 is closely upregulated by some cytokines (especially IFN-γ), of which the release is an inherent event of immune response. Therefore, when CAR-T cells attack solid tumor cells, such a negative feedback regulation is generally inevitable.

To overcome this dilemma, a PD-1-CD28 fusion receptor was firstly designed in 2012 by Prosser et al. at the City of Hope National Medical Center [57], and this chimeric receptor was expected to switch original inhibitory signals into activation signals. This structure was designed because PD-1 and CD28 both belong to the CD28 superfamily, and the compatibility of function mechanisms between them had been demonstrated earlier. The authors fused the extracellular part of PD-1 with the intracellular part of CD28. When the extracellular part engaged with PD-L1, an activation signal was transmitted instead of inhibitory signal with CD28 cytoplasmic domain (Fig. 5). Along with activation via CAR, the switch receptor could enhance cytokine release, proliferation, and cytotoxicity of CAR-T cells.

Fig. 5
figure 5

Chimeric receptors can convert inhibitory signals into activating ones

In 2015, a Germany research group optimized this structure, in which the CD28 transmembrane domain was replaced by the analog of PD-1 [58]. The authors demonstrated that the YMNM motif of the CD28 was required for optimal cytokine secretion and the PYAP motif was essential for both cytokine production and proliferation.

In 2016, Liu et al. from Carl June’s lab demonstrated that this switch receptor was able to augment the cytotoxicity of CAR-Ts to large established solid tumors [59]. And the experiment date showed that the PD1-CD28 receptor was superior in controlling tumor burden compared with PD-1 blocking antibody.

In addition, blocking PD-1 signal can effectively reverse the exhaustion of CAR-T cells [60].

Following a similar design concept, CTLA-4, lymphocyte activation gene-3(LAG-3), and mucin-domain containing-3 (Tim-3) based switch receptors could also be synthesized and tested. Therefore, by switching the inhibitory signals, these immunosuppressive molecules can also be the targets of CAR-T cells to boost their antitumor functions.


Target selection is the most fundamental factor determining the potential of CAR-T therapy, and its selection criteria are not monotonous. In this review, we summarized and discussed what constituted an ideal target based on existing clinical data. We believe that coverage is the primary factor to be considered, which directly determines the ceiling of CAR-T therapy. Specificity is also a basic factor to be considered. It can affect the effectiveness of CAR-T treatment by influencing the treatment intensity. In addition, the expression of an ideal target must be fixed. Otherwise, rapid and frequent target loss will lead to the failure of CAR-T treatment.

For the treatment of solid tumors, it is difficult to get the ideal target like CD19. Therefore, the role of CAR-T therapy should not be limited to killing cancer cells directly, such as activating endogenous tumor immune response and destroying the growth environment of tumors. In addition, some new target utilization strategies might be meaningful to solve specific problems, such as combinatorial utilization of multiple targets and switching inhibitory signals.

Availability of data and materials

All data generated or analyzed in this study are included in this article. Other data that are relevant to this article are available from the corresponding author upon reasonable request.



B cell acute lymphocytic leukemia


Chimeric antigen receptor-modified T


Complete remission rate


Cytokine release syndrome


Cytotoxic T lymphocyte-associated protein-4


Dendritic cells


Human leukocyte antigen


Lymphocyte activation gene-3


Multiple myeloma


Programmed death-1


Programmed death-ligand 1


Programmed death-ligand 2


T Cell receptor


Mucin-domain containing-3


Wilms’ tumor-1


  1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget. 2015;6(32):33961–71.

    PubMed  PubMed Central  Google Scholar 

  4. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019;130:2210–21.

    Article  PubMed  Google Scholar 

  7. Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543–51.

    Article  CAS  Google Scholar 

  8. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.

    Article  CAS  PubMed  Google Scholar 

  9. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155(2):160–75.

    Article  CAS  PubMed  Google Scholar 

  12. Liu L, Sommermeyer D, Cabanov A, Kosasih P, Hill T, Riddell SR. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol. 2016;34(4):430–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol. 2015;195(3):755–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22(2):72–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, et al. Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. 2013;62(10):1563–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009;4(3):e4749.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.

    Article  CAS  PubMed  Google Scholar 

  21. Liu D, Zhao J. Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol. 2018;11(1):121.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J, et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol. 2018;11(1):128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11(1):7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–6.

    Article  PubMed  CAS  Google Scholar 

  28. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  29. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol. 2018;11(1):60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Carter RH, Wang Y, Brooks S. Role of CD19 signal transduction in B cell biology. Immunol Res. 2002;26(1-3):45–54.

    Article  CAS  PubMed  Google Scholar 

  32. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–85.

    Article  CAS  PubMed  Google Scholar 

  33. Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814–26.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596–605.

    Article  CAS  PubMed  Google Scholar 

  35. Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W, et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer. 2017;5:42.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B Cells. Cancer Immunol Res. 2016;4(6):498–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71–5.

    Article  CAS  PubMed  Google Scholar 

  39. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Ikeda H, Akahori Y, Orito Y, Miyahara Y, Amaishi Y, Okamoto S, et al. 193. Efficacy and safety of immunotherapy with chimeric antigen receptor targeting WT1 and HLA-A24:02 pMHC Complex2016.

  41. Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017;31(8):1788–97.

    Article  CAS  PubMed  Google Scholar 

  42. Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015;75(14):2800–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21(8):1611–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2(2):154–66.

    Article  CAS  PubMed  Google Scholar 

  45. Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res. 2015;3(1):68–84.

    Article  CAS  PubMed  Google Scholar 

  46. Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 2013;73(11):3371–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Guo Y, Feng K, Wang Y, Han W. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. Protein Cell. 2018;9(6):516–26.

    Article  CAS  PubMed  Google Scholar 

  48. Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):1844–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113(4):E459–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018;173(6):1426–38 e11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8):e458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113(4):E450–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017;27(1):11–37.

    Article  PubMed  CAS  Google Scholar 

  55. Ramachandran M, Dimberg A, Essand M. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. Semin Cancer Biol. 2017;45:23–35.

    Article  CAS  PubMed  Google Scholar 

  56. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346–51.

    Article  CAS  PubMed  Google Scholar 

  57. Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3-4):263–72.

    Article  CAS  PubMed  Google Scholar 

  58. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. 2015;107(8):djv146.

  59. Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76(6):1578–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references


Not applicable.


This research was supported by the grants from the National Natural Science Foundation of China (No. 81830002 and 31870873 to WDH, No. 81703044 to JSW), the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504 to WDH), and the Sanya Medical and Health Technology Innovation Project (No.2016YW23 to JB).

Author information

Authors and Affiliations



JSW and WDH conceived and designed the study. JSW, XH, and JB collected and interpreted the data. JSW and WDH wrote the manuscript. XH and JB provided the technical or material support. WDH supervised the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Weidong Han.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

No individual data were used in this study.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, J., Han, X., Bo, J. et al. Target selection for CAR-T therapy. J Hematol Oncol 12, 62 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: